Semaglutide Treatment for Hyperglycaemia After Renal Transplantation
NCT05702931 on ClinicalTrials.gov · last registry update 2025-12-29
Recruiting now, toward 104 participants. Due to report December 2027, alongside 38 other tracked readouts that quarter. Primary outcome, as filed: Mean sensor glucose (mmol/L). Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 19 September 2024 — 2 years so far. semaglutide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- RECRUITING
- Phase
- P4
- Drug
- semaglutideRybelsus, Wegovy, Ozempic
- Sponsor
- Rigshospitalet, Denmark
- Sponsor type
- Other
- Enrollment
- 104
- Started
- 2024-09-19
- Primary completion
- 2027-12 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Mean sensor glucose (mmol/L)
Conditions studied
Hyperglycemia · Renal Transplant Complication Primary Non-Function · Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.